ReCode Therapeutics secured up to $15 million in a corporate round led by the Cystic Fibrosis Foundation to develop a gene editing therapy for cystic fibrosis.

Nov 18, 2024•8 months ago

Amount Raised

$15 Million

Menlo ParkBiotechnologyHealth Care

Investors

Cystic Fibrosis Foundation

Description

The Cystic Fibrosis Foundation has agreed to invest up to $15 million in ReCode Therapeutics to support their collaboration with Intellia Therapeutics. The funding will aid in the development of a gene editing therapy intended for lung cells of individuals suffering from cystic fibrosis.

Company Information

Company

ReCode Therapeutics

Location

1455 ADAMS DRIVE

Menlo Park, California, United States

About

ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

ReCode Therapeutics secured up to $15 million in a corporate round led by the Cystic Fibrosis Foundation to develop a gene editing therapy for cystic fibrosis.

Investors

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Related People

Company Information